277 related articles for article (PubMed ID: 31040243)
1. An Experimental Group A
Rivera-Hernandez T; Carnathan DG; Jones S; Cork AJ; Davies MR; Moyle PM; Toth I; Batzloff MR; McCarthy J; Nizet V; Goldblatt D; Silvestri G; Walker MJ
mBio; 2019 Apr; 10(2):. PubMed ID: 31040243
[TBL] [Abstract][Full Text] [Related]
2. Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.
Rivera-Hernandez T; Pandey M; Henningham A; Cole J; Choudhury B; Cork AJ; Gillen CM; Ghaffar KA; West NP; Silvestri G; Good MF; Moyle PM; Toth I; Nizet V; Batzloff MR; Walker MJ
mBio; 2016 Jun; 7(3):. PubMed ID: 27302756
[TBL] [Abstract][Full Text] [Related]
3. Vaccine-Induced Th1-Type Response Protects against Invasive Group A
Rivera-Hernandez T; Rhyme MS; Cork AJ; Jones S; Segui-Perez C; Brunner L; Richter J; Petrovsky N; Lawrenz M; Goldblatt D; Collin N; Walker MJ
mBio; 2020 Mar; 11(2):. PubMed ID: 32156809
[TBL] [Abstract][Full Text] [Related]
4. Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development.
Williamson DA; Smeesters PR; Steer AC; Morgan J; Davies M; Carter P; Upton A; Tong SY; Fraser J; Moreland NJ
BMC Infect Dis; 2016 Oct; 16(1):561. PubMed ID: 27733129
[TBL] [Abstract][Full Text] [Related]
5. Clinical development strategy for a candidate group A streptococcal vaccine.
Schödel F; Moreland NJ; Wittes JT; Mulholland K; Frazer I; Steer AC; Fraser JD; Carapetis J
Vaccine; 2017 Apr; 35(16):2007-2014. PubMed ID: 28318768
[TBL] [Abstract][Full Text] [Related]
6. Increased Breadth of Group A Streptococcus Antibody Responses in Children With Acute Rheumatic Fever Compared to Precursor Pharyngitis and Skin Infections.
Whitcombe AL; McGregor R; Bennett J; Gurney JK; Williamson DA; Baker MG; Moreland NJ
J Infect Dis; 2022 Aug; 226(1):167-176. PubMed ID: 35134931
[TBL] [Abstract][Full Text] [Related]
7. Comparison of rhesus and cynomolgus macaques in a Streptococcus pyogenes infection model for vaccine evaluation.
Skinner JM; Caro-Aguilar IC; Payne AM; Indrawati L; Fontenot J; Heinrichs JH
Microb Pathog; 2011 Jan; 50(1):39-47. PubMed ID: 21035535
[TBL] [Abstract][Full Text] [Related]
8. An eight-plex immunoassay for Group A streptococcus serology and vaccine development.
Whitcombe AL; Han F; McAlister SM; Kirkham LS; Young PG; Ritchie SR; Atatoa Carr P; Proft T; Moreland NJ
J Immunol Methods; 2022 Jan; 500():113194. PubMed ID: 34801540
[TBL] [Abstract][Full Text] [Related]
9. Immune response against M protein-conserved region peptides from prevalent group A Streptococcus in a North Indian population.
Gupta VK; Sekhar S; Dhanda V; Toor D; Kumar R; Chakraborti A
J Microbiol Immunol Infect; 2016 Jun; 49(3):352-8. PubMed ID: 25087198
[TBL] [Abstract][Full Text] [Related]
10. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils.
Park HS; Cleary PP
Infect Immun; 2005 Dec; 73(12):7878-86. PubMed ID: 16299278
[TBL] [Abstract][Full Text] [Related]
11. Vaccine Approaches To Protect against Group A Streptococcal Pharyngitis.
Fischetti VA
Microbiol Spectr; 2019 May; 7(3):. PubMed ID: 31111819
[TBL] [Abstract][Full Text] [Related]
12. Application of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenes.
Nakakana U; Serry-Bangura A; Edem BE; Tessitore P; Di Cesare L; Moriel DG; Podda A; De Ryck IS; Arora AK
Drugs R D; 2024 Mar; 24(1):1-12. PubMed ID: 38494581
[TBL] [Abstract][Full Text] [Related]
13. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.
Tsoi SK; Smeesters PR; Frost HR; Licciardi P; Steer AC
J Immunol Res; 2015; 2015():167089. PubMed ID: 26101780
[TBL] [Abstract][Full Text] [Related]
14. Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development.
Shet A; Kaplan EL; Johnson DR; Cleary PP
J Infect Dis; 2003 Sep; 188(6):809-17. PubMed ID: 12964111
[TBL] [Abstract][Full Text] [Related]
15. A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes.
Bi S; Xu M; Zhou Y; Xing X; Shen A; Wang B
mBio; 2019 Nov; 10(6):. PubMed ID: 31772056
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults.
Di Pierro F; Adami T; Rapacioli G; Giardini N; Streitberger C
Expert Opin Biol Ther; 2013 Mar; 13(3):339-43. PubMed ID: 23286823
[TBL] [Abstract][Full Text] [Related]
17. Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.
Batzloff MR; Fane A; Gorton D; Pandey M; Rivera-Hernandez T; Calcutt A; Yeung G; Hartas J; Johnson L; Rush CM; McCarthy J; Ketheesan N; Good MF
Hum Vaccin Immunother; 2016 Dec; 12(12):3089-3096. PubMed ID: 27541593
[TBL] [Abstract][Full Text] [Related]
18. Potential coverage of a multivalent M protein-based group A streptococcal vaccine.
Dale JB; Penfound TA; Tamboura B; Sow SO; Nataro JP; Tapia M; Kotloff KL
Vaccine; 2013 Mar; 31(12):1576-81. PubMed ID: 23375817
[TBL] [Abstract][Full Text] [Related]
19. Vaccine development for group A streptococcus infections and associated disease.
Batzloff MR; Sriprakash KS; Good MF
Curr Drug Targets; 2004 Jan; 5(1):57-69. PubMed ID: 14738218
[TBL] [Abstract][Full Text] [Related]
20. Development of Group A streptococcal vaccines: an unmet global health need.
Sheel M; Moreland NJ; Fraser JD; Carapetis J
Expert Rev Vaccines; 2016; 15(2):227-38. PubMed ID: 26559880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
